BioNTech SE (BVMF:B1NT34)

Market Cap	118.10B -10.9%
Revenue (ttm)	18.56B +4.3%
Net Income	-7.35B
EPS	-30.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	1,493
Open	29.31
Previous Close	28.83
Day's Range	29.31 - 29.31
52-Week Range	25.78 - 43.61
Beta	1.59
RSI	43.14
Earnings Date	May 5, 2026

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 7,807
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1NT34

Financial Performance

In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.

Financial numbers in EUR